BMS-986178 clinical trials
Also written BMS-986178.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses BMS-986178 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Ronald Levy (2) · Bristol-Myers Squibb (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BMS-986178 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasCompletedPhase 1Ronald LevyNCT03410901Written as Anti-OX40 Antibody BMS 986178
- SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid MalignanciesCompletedPhase 1Ronald LevyNCT03831295Written as Anti-OX40 Antibody BMS 986178
- An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedPhase 1/2Bristol-Myers SquibbNCT02737475Written as BMS-986178
Codes
What other systems call BMS-986178 · ClinicalTrials.gg INT017562
- UNII (FDA) P9XVH8H2HFBMS-986178One source FDA
- NCI Thesaurus C128026Anti-OX40 Antibody BMS 986178One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | P9XVH8H2HF | BMS-986178 | One source FDA |
| NCI Thesaurus | C128026 | Anti-OX40 Antibody BMS 986178 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.